Teloxantrone HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206748

CAS#: 132937-88-3 (HCl)

Description: Teloxantrone, also known as Moxantrazole, CI-937; DuP-937; NSC-355644; PD-113309, is a DNA topoisomerase II inhibitor potentially for the treatment of solid tumors.

Chemical Structure

img
Teloxantrone HCl
CAS# 132937-88-3 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 206748
Name: Teloxantrone HCl
CAS#: 132937-88-3 (HCl)
Chemical Formula: C21H27Cl2N5O4
Exact Mass: 411.19
Molecular Weight: 484.378
Elemental Analysis: C, 52.07; H, 5.62; Cl, 14.64; N, 14.46; O, 13.21

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 132937-88-3 (HCl)   91441-48-4 (free base)   123830-79-5 (HCl)    

Synonym: Moxantrazole; Teloxantrone; CI-937; DuP-937; NSC-355644; PD-113309; CI937; DuP937; NSC355644; PD113309.

IUPAC/Chemical Name: 7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)dibenzo[cd,g]indazol-6(2H)-one dihydrochloride

InChi Key: SZTBQTTVEIEAQV-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H25N5O4.2ClH/c1-22-6-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27;;/h2-5,22-24,27-29H,6-11H2,1H3;2*1H

SMILES Code: O=C1C2=C3C(N(CCNCCO)N=C3C4=C(O)C=CC(O)=C14)=CC=C2NCCNC.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 484.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Armand JP. New anticancer drugs in Europe. Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:70-93. Review. PubMed PMID: 9210890.

2: Gogas H, Mansi JL. New drugs. The anthrapyrazoles. Cancer Treat Rev. 1996 Nov;21(6):541-52. Review. PubMed PMID: 8599804.

3: Renner U, Blanz J, Freund S, Waidelich D, Ehninger G, Zeller KP. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates. Drug Metab Dispos. 1995 Jan;23(1):94-101. PubMed PMID: 7720531.

4: Raghavan K, Nemeth G, Gray D, Hussain MA. Stabilization of an anthrapyrazole antitumour agent, DuP 937, on complexation with heptakis(2,6-di-O-methyl)-beta-cyclodextrin in aqueous solution. J Pharm Biomed Anal. 1994 Oct;12(10):1259-64. PubMed PMID: 7841220.

5: Leteurtre F, Kohlhagen G, Paull KD, Pommier Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44. PubMed PMID: 8040892.

6: Bélanger K, Jolivet J, Maroun J, Stewart D, Grillo-Lopez A, Whitfield L, Wainman N, Eisenhauer E. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Invest New Drugs. 1993 Nov;11(4):301-8. PubMed PMID: 8157472.

7: Shore T, Eisenhauer E, Quirt I, Belanger K, Lohmann R, Silver H, Wielgosz G. A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG). Ann Oncol. 1993 Sep;4(8):695-6. PubMed PMID: 8241003.

8: Gregg RW, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol. 1993 Sep;4(8):693-4. PubMed PMID: 8241002.

9: Maroun JA, Skillings J, MacCormick R, Potvin M, Wielgosz G, Davidson JR, Eisenhauer E. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trial Group study. Invest New Drugs. 1993 May-Aug;11(2-3):235-7. PubMed PMID: 8262739.

10: Erlichman C, Moore M, Kerr IG, Wong B, Eisenhauer E, Zee B, Whitfield LR. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937). Cancer Res. 1991 Dec 1;51(23 Pt 1):6317-22. PubMed PMID: 1933893.

11: Wong B, Nordblom G, Chang T, Whitfield L. Lack of dose proportional pharmacokinetics for CI-937, an anthrapyrazole DNA intercalator, in mice. Res Commun Chem Pathol Pharmacol. 1989 Nov;66(2):191-202. PubMed PMID: 2602655.

12: Nordblom GD, Pachla LA, Chang T, Whitfield LR, Showalter HD. Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats. Cancer Res. 1989 Oct 1;49(19):5345-51. PubMed PMID: 2766301.

13: Frank P, Novak RF. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochem Biophys Res Commun. 1986 Nov 14;140(3):797-807. PubMed PMID: 3778486.

14: Reszka K, Kolodziejczyk P, Lown JW. Photosensitization by antitumor agents 2: anthrapyrazole-photosensitized oxidation of ascorbic acid and 3,4-dihydroxyphenylalanine. J Free Radic Biol Med. 1986;2(3):203-11. PubMed PMID: 3033048.

15: Fry DW, Boritzki TJ, Besserer JA, Jackson RC. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol. 1985 Oct 1;34(19):3499-508. PubMed PMID: 2413861.